BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-97637

Clone Vicky-1 was used by HLDA to establish CD designation.
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP1-97637
NBP1-97637-100ug
NBP1-97637SS
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

ELISA, Flow Cytometry, Functional, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot

Cited:

Flow Cytometry

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG1 Clone # Vicky-1

Format

BSA Free

Concentration

1.0 mg/ml

View all BCMA/TNFRSF17 Antibodies »

Product Specifications

Immunogen

Recombinant human BCMA extracellular domain (aa 2-54).

Reactivity Notes

Does not cross-react with Mouse BCMA.

Clonality

Monoclonal

Host

Rat

Isotype

IgG1

Scientific Data Images for BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free

Immunohistochemistry: BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free [NBP1-97637]

Immunohistochemistry: BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free [NBP1-97637]

Immunohistochemistry: BCMA/TNFRSF17 Antibody (Vicky-1) [NBP1-97637] - Immunostaining of HEK 293 cells transfected with a human BCMA expression plasmid (left panel), or mock transfected (right panel). Method: 3 days after transfection of cells with the indicated constructs, cells were fixed with acetone or 4% formaldehyde for 5 min. at room temperature. Slides were blocked with normal IgG, and incubated for 1 hour with 5ug/ml MAb to BCMA (human) (Vicky-1) in 1% BSA in 1x PBS. After washes in PBS, samples were incubated with the secondary antibody for 1 hour, washed in PBS and revealed with StreptABComplex/HRP (Vector) and AEC.
Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free [NBP1-97637]

Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free [NBP1-97637]

Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) [NBP1-97637] - Analysis using the PE conjugate of NBP1-97637. Staining of 10^6 U266 cells using BCMA (human), mAb (Vicky-1) (PE conjugate) at a concentration of 10ug/ml.
Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free [NBP1-97637]

Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free [NBP1-97637]

Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) [NBP1-97637] - Detection of endogenous human BCMA with MAb to BCMA (human) (Vicky-1). Method: U266 cells (2x10^5) were incubated on ice for 30 min. with 0.2ug of MAb to BCMA (human) (Vicky-1) or an isotype control in 25ul FACS buffer (PBS, 5% fetal calf serum, 0.02% azide). The primary antibody was revealed with PAb to Rat IgG (R-PE) and then analyzed by flow cytometry.
View 1 more images

Applications for BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free

Application
Recommended Usage

ELISA

1:100-1:2000

Flow Cytometry

1:10-1:1000

Immunocytochemistry/ Immunofluorescence

1:10-1:2000

Western Blot

1:100-1:2000
Application Notes
Use in WB was reported in the scientific literature (PMID: 20454508). Functional Application: blocks binding of BAFF to human BCMA.

Reviewed Applications

Read 1 review rated 4 using NBP1-97637 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: BCMA/TNFRSF17

B cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a type III transmembrane glycoprotein that plays a role in B cell maturation and differentiation into plasma cells and is a therapeutic target for treatment of multiple myeloma (MM) (1,2). BMCA is synthesized as a protein of 184 amino acids (aa) in length with a theoretical molecular weight of 20.2 kDa consisting of an extracellular N-terminus containing 6 cysteine residues, a transmembrane domain, and an intracellular tumor necrosis factor (TRAF) binding domain (1). BCMA is functionally similar to two other TNFR superfamily members, B cell activation factor receptor (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) (1,2). BCMA is primarily expressed on plasmablasts, plasma cells, and late-stage B cells (1,2).

BCMA has two agonistic ligands: BAFF and a proliferation-inducing ligand (APRIL) (1,2). APRIL has higher affinity for BCMA than BAFF and the binding is mediated by CD138/syndeclin-1 (2,3). Activation of BCMA promotes the growth and survival of plasma cells, or MM cells in disease, through several signaling pathways such as NFkappaB, MEK/ERK, AKT, JNK, and p38 (1,2). In MM cells the BCMA activation and downstream signaling cascade functions to upregulate antiapoptotic proteins including Bcl-2, Bcl-xL, and Mcl-1 and protect the cells against therapeutic agents like dexamethasone (2,3).

Given its specific expression on plasma cells but not memory B cells, naive B cells, or hematopoietic stem cells, BCMA has garnered much interest as a therapeutic target for the treatment of MM (1-4). Current BCMA-targeted immunotherapy strategies include antibody-drug conjugates (ADC), chimeric antigen receptor (CAR) T cells, bispecific T cell engager (BiTE), and bispecific/trispecific antibodies (1-4). CAR T cell therapy in particular has demonstrated promising clinical results (2,4). Still, more research needs to be done to improve the efficacy and risk of relapse following CAR T cell therapy and may also include targeting additional antigens in combination with BCMA or utilizing pharmacological agents to increase antigen density (4).

References

1. Yu, B., Jiang, T., & Liu, D. (2020). BCMA-targeted immunotherapy for multiple myeloma. Journal of hematology & oncology, 13(1), 125. https://doi.org/10.1186/s13045-020-00962-7

2. Cho, S. F., Anderson, K. C., & Tai, Y. T. (2018). Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Frontiers in immunology, 9, 1821. https://doi.org/10.3389/fimmu.2018.01821

3. Dalla Palma, B., Marchica, V., Catarozzo, M. T., Giuliani, N., & Accardi, F. (2020). Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. Journal of clinical medicine, 9(9), 3022. https://doi.org/10.3390/jcm9093022

4. Mikkilineni, L., & Kochenderfer, J. N. (2021). CAR T cell therapies for patients with multiple myeloma. Nature reviews. Clinical oncology, 18(2), 71-84. https://doi.org/10.1038/s41571-020-0427-6

Long Name

B Cell Maturation Factor

Alternate Names

CD269, TNFRSF13A, TNFRSF17

Gene Symbol

TNFRSF17

Additional BCMA/TNFRSF17 Products

Product Documents for BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for BCMA/TNFRSF17 Antibody (Vicky-1) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.